Novel Therapeutic Approach for Human T-cell Malignancies

This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels. Interactions between drugs capable of activating the apoptotic process (e.g., Venetoclax) and drugs capable of altering ROS homeostasis (e.g., inhibitors of the enzyme glucose-6-phosphate dehydrogenase) will be examined. The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory, and then will be assayed ex vivo in cells obtained from patients with resistant/refractory T-cell neoplasms.

NCT Number	NCT06600568
Lead Sponsor	Istituto Oncologico Veneto IRCCS Collaborators: Istituto Nazionale Tumori IRCSS-Fondazione G.Pascale
Conditions	T-Cell Leukemia/Lymphoma, Adult
Enrollment	120 participants
Start Date	2025-03-18
Primary Completion	2027-03-01 (estimated)
Study Completion	2027-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-06